Alexander Azoy Sells 2,376 Shares of Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CAO Alexander Azoy sold 2,376 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $21.88, for a total transaction of $51,986.88. Following the transaction, the chief accounting officer directly owned 24,987 shares in the company, valued at $546,715.56. This represents a 8.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Alexander Azoy also recently made the following trade(s):

• On Thursday, December 18th, Alexander Azoy sold 4,343 shares of Arcus Biosciences stock. The shares were sold at an average price of $22.25, for a total value of $96,631.75.
• On Wednesday, December 17th, Alexander Azoy sold 2,113 shares of Arcus Biosciences stock. The stock was sold at an average price of $22.16, for a total value of $46,824.08.
• On Wednesday, November 26th, Alexander Azoy sold 1,900 shares of Arcus Biosciences stock. The stock was sold at an average price of $26.00, for a total value of $49,400.00.
• On Monday, September 29th, Alexander Azoy sold 2,831 shares of Arcus Biosciences stock. The shares were sold at an average price of $13.00, for a total value of $36,803.00.

Arcus Biosciences Price Performance

Shares of NYSE:RCUS traded down $0.26 during trading on Thursday, reaching $22.02. 1,175,874 shares of the company traded hands, compared to its average volume of 1,200,446. The firm has a market capitalization of $2.38 billion, a PE ratio of -6.40 and a beta of 0.75. Arcus Biosciences, Inc. has a 52 week low of $6.50 and a 52 week high of $26.40. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.22. The company’s 50 day moving average is $20.82 and its two-hundred day moving average is $13.98.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The company had revenue of $26.00 million for the quarter, compared to analysts’ expectations of $19.89 million. During the same quarter last year, the business earned ($1.00) earnings per share. Arcus Biosciences’s revenue was down 45.8% on a year-over-year basis. As a group, sell-side analysts predict that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Bank of America boosted their target price on shares of Arcus Biosciences from $17.00 to $26.00 and gave the company a “neutral” rating in a research report on Friday, November 28th. HC Wainwright boosted their price objective on shares of Arcus Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Truist Financial set a $30.00 target price on Arcus Biosciences in a research note on Friday, December 12th. Wedbush set a $35.00 price target on Arcus Biosciences and gave the company an “outperform” rating in a research note on Wednesday, October 29th. Finally, The Goldman Sachs Group boosted their price target on Arcus Biosciences from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $28.89.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in Arcus Biosciences by 24.1% during the 1st quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company’s stock worth $52,499,000 after acquiring an additional 1,298,584 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Arcus Biosciences by 23.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 714,002 shares of the company’s stock worth $5,605,000 after purchasing an additional 134,379 shares during the period. Maryland State Retirement & Pension System lifted its holdings in shares of Arcus Biosciences by 10.9% during the first quarter. Maryland State Retirement & Pension System now owns 20,202 shares of the company’s stock worth $159,000 after purchasing an additional 1,986 shares during the period. Swiss National Bank grew its stake in shares of Arcus Biosciences by 35.9% in the first quarter. Swiss National Bank now owns 133,596 shares of the company’s stock worth $1,049,000 after purchasing an additional 35,300 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in Arcus Biosciences by 24.5% in the first quarter. Invesco Ltd. now owns 254,024 shares of the company’s stock valued at $1,994,000 after purchasing an additional 50,037 shares during the period. 92.89% of the stock is currently owned by institutional investors.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.